Recent advances in targeted small‐molecule inhibitor therapy for non–small‐cell lung cancer—an update
What is known and objective Targeted small molecule EGFR Tyrosine Kinase Inhibitors
(TKI's) and the Anaplastic Lymphoma Kinase (ALK) inhibitors have been promising tools for …
(TKI's) and the Anaplastic Lymphoma Kinase (ALK) inhibitors have been promising tools for …
[HTML][HTML] Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial
L Paz-Ares, EH Tan, K O'Byrne, L Zhang, V Hirsh… - Annals of …, 2017 - Elsevier
ABSTRACT Background In LUX-Lung 7, the irreversible ErbB family blocker, afatinib,
significantly improved progression-free survival (PFS), time-to-treatment failure (TTF) and …
significantly improved progression-free survival (PFS), time-to-treatment failure (TTF) and …
[HTML][HTML] Anlotinib combined with gefitinib can significantly improve the proliferation of epidermal growth factor receptor-mutant advanced non-small cell lung cancer in …
T Li, Y Qian, C Zhang, J Uchino… - Translational Lung …, 2021 - ncbi.nlm.nih.gov
Background The effect of anlotinib combined with epidermal growth factor receptor TKIs
(EGFR-TKIs) in patients with advanced non-small cell lung cancer (NSCLC) with acquired …
(EGFR-TKIs) in patients with advanced non-small cell lung cancer (NSCLC) with acquired …
[HTML][HTML] The Efficacy and Safety of Anlotinib Plus Etoposide with Cisplatin/Carboplatin in the First-Line Treatment of Lung Cancer: A Phase II Clinical Study
X Lv, Y Liu, Y Feng, H Liang, W Zhi - Journal of Cancer, 2024 - ncbi.nlm.nih.gov
Background: The primary aim of this phase II clinical study was to assess the safety and
efficacy of combining anlotinib, etoposide, and platinum-based drugs as a first-line treatment …
efficacy of combining anlotinib, etoposide, and platinum-based drugs as a first-line treatment …
P2. 03-028 third generation EGFR inhibitor AST2818 (alflutinib) in NSCLC patients with EGFR T790M mutation: A phase1/2 multi-center clinical trial
Y Shi, X Hu, S Zhang, N Yang, Y Zhang, W Li… - Journal of Thoracic …, 2017 - jto.org
Background AST2818 (Alflutinib) was designed to inhibit EGFR active mutations as well as
the T790M acquired resistant mutation. The purpose of this study was to determine the …
the T790M acquired resistant mutation. The purpose of this study was to determine the …
Prognostic factors of patients with advanced lung cancer treated with anlotinib: a retrospective cohort study
B Fan, X Tan, Y Lou, Y Zheng… - Journal of International …, 2021 - journals.sagepub.com
Objective Our study aimed to evaluate the main factors affecting the efficacy of anlotinib to
determine the therapeutically dominant populations. Methods The medical records of …
determine the therapeutically dominant populations. Methods The medical records of …
[HTML][HTML] CNS efficacy of afatinib as first-line treatment in advanced non-small cell lung cancer patients with EGFR mutations
L Kang, J Mai, W Liang, Q Zou, C Huang, Y Lin… - Frontiers in …, 2023 - frontiersin.org
Background Afatinib is a potent, irreversible second-generation epidermal growth factor
receptor (EGFR) tyrosine kinase inhibitor which has demonstrated efficacy in advanced non …
receptor (EGFR) tyrosine kinase inhibitor which has demonstrated efficacy in advanced non …
AENEAS: A randomized phase III trial of aumolertinib versus gefitinib as first-line therapy for locally advanced or metastaticnon–small-cell lung cancer with EGFR exon …
S Lu, X Dong, H Jian, J Chen, G Chen… - Journal of Clinical …, 2022 - ascopubs.org
PURPOSE Aumolertinib (formerly almonertinib; HS-10296) is a novel third-generation
epidermal growth factor receptor tyrosine kinase inhibitor approved in China. This double …
epidermal growth factor receptor tyrosine kinase inhibitor approved in China. This double …
[HTML][HTML] Anlotinib plus docetaxel vs. docetaxel alone for advanced non-small-cell lung cancer patients who failed first-line treatment: A multicenter, randomized phase …
X Pu, Z Xiao, J Li, Z Wu, Z Ma, J Weng, M Xiao, Y Chen… - Lung Cancer, 2024 - Elsevier
Objectives Given the modest efficacy of docetaxel in advanced non-small cell lung cancer
(NSCLC), this study assesses the therapeutic potential and safety profile of anlotinib in …
(NSCLC), this study assesses the therapeutic potential and safety profile of anlotinib in …
[HTML][HTML] LBA2_PR Afatinib (A) vs gefitinib (G) as first-line treatment for patients (pts) with advanced non-small cell lung cancer (NSCLC) harboring activating EGFR …
K Park, EH Tan, L Zhang, V Hirsh… - Annals of …, 2015 - annalsofoncology.org
Aim: The irreversible ErbB family blocker A and the reversible EGFR tyrosine kinase inhibitor
G are approved for first-line treatment of advanced EGFR-mutant (m+) NSCLC. We have …
G are approved for first-line treatment of advanced EGFR-mutant (m+) NSCLC. We have …